Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
By Adria Calatayud
Roche Holding said an experimental obesity drug it is jointly developing with Denmark's Zealand Pharma met its primary goal in a midstage trial by helping patients lose weight.
The drug candidate, petrelintide, led to meaningful weight loss in people who are overweight and living with obesity when administered in once-weekly injections after 28 weeks of treatment, meeting the main goal of the Phase 2 study, the Swiss pharmaceutical giant said Thursday. At week 42, petrelintide achieved a mean body-weight reduction of up to 10.7%, it added.
The company said the data support further development of the drug candidate in chronic weight management on its own or in combination with other drugs due to its tolerability.
The company said petrelintide showed a favorable tolerability profile, comparable to placebo.
Petrelintide is one of several obesity-drug candidates Roche has in its pipeline, as the drugmaker seeks to build a franchise to compete with Eli Lilly and Novo Nordisk. The company previously said it sees annual peak sales potential of more than $3 billion for the drug candidate.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 05, 2026 14:46 ET (19:46 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States